Eficacia, seguridad y tolerabilidad de V937 administrado por vía intravenosa o intratumoral con pembrolizumab frente a pembrolizumab solo en participantes con melanoma avanzado/metastásico
This is a Phase 2 study to assess the efficacy, safety, and tolerability of V937 administered both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab (MK-3475) versus pembrolizumab alone